Search

Your search keyword '"Lohaus F"' showing total 7 results
Start Over Author "Lohaus F" Language undetermined
7 results on '"Lohaus F"'

1. Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma using different imaging modalities

Author

Gkika, E, Kostyszyn, D, Fechter, T, Moustakis, C, Ernst, F, Boda-Heggemann, J, Sarria, G, Dieckmann, K, Dobiasch, S, Duma, M N, Eberle, F, Kroeger, K, Häussler, B, Izaguirre, V, Jazmati, D, Lautenschläger, S, Lohaus, F, Mantel, F, Menzel, J, Pachmann, S, Pavic, M, Radlanski, K, Riesterer, O, Gerum, S, Röder, F, Willner, J, Barczyk, S, Imhoff, D, Blanck, O, Wittig, A, et al, and Guckenberger, M

Published
2023
Full Text
View/download PDF

2. Stereotactic radiosurgery and radiotherapy for resected brain metastases: current pattern of care in the Radiosurgery and Stereotactic Radiotherapy Working Group of the German Association for Radiation Oncology (DEGRO)

Author

Rogers, S, Baumert, B, Blanck, O, Böhmer, D, Boström, J, Engenhart-Cabillic, R, Ermis, E, Exner, S, Guckenberger, M, Habermehl, D, Hemmatazad, H, Henke, G, Lohaus, F, Lux, S, Mai, S, Minasch, D, Rezazadeh, A, Steffal, C, Temming, S, Wittig, A, Zweifel, C, Riesterer, O, and Combs, S

Subjects
Oncology, Brain Neoplasms, Radiation Oncology, Brain, Humans, Radiology, Nuclear Medicine and imaging, Dose Fractionation, Radiation, 610 Medizin und Gesundheit, Radiosurgery
Abstract

PURPOSE Preoperative stereotactic radiosurgery (SRS) of brain metastases may achieve similar local control and better leptomeningeal control rates than postoperative fractionated stereotactic radiotherapy (FSRT) in patients treated with elective metastasectomy. To plan a multicentre trial of preoperative SRS compared with postoperative FSRT, a survey of experts was conducted to determine current practice. METHODS A survey with 15 questions was distributed to the DEGRO Radiosurgery and Stereotactic Radiotherapy Working Group. Participants were asked under what circumstances they offered SRS, FSRT, partial and/or whole brain radiotherapy before or after resection of a brain metastasis, as well as the feasibility of preoperative stereotactic radiosurgery and neurosurgical resection within 6 days. RESULTS Of 25 participants from 24 centres, 22 completed 100% of the questions. 24 respondents were radiation oncologists and 1 was a neurosurgeon. All 24 centres have one or more dedicated radiosurgery platform and all offer postoperative FSRT. Preoperative SRS is offered by 4/24 (16.7%) centres, and 9/24 (37.5%) sometimes recommend single-fraction postoperative SRS. Partial brain irradiation is offered by 8/24 (33.3%) centres and 12/24 (50%) occasionally recommend whole-brain irradiation. Two centres are participating in clinical trials of preoperative SRS. SRS techniques and fractionation varied between centres. CONCLUSION All responding centres currently offer postoperative FSRT after brain metastasectomy. Approximately one third offer single-fraction postoperative SRS and four already perform preoperative SRS. With regard to potential co-investigators, 18 were identified for the PREOP‑2 multicentre trial, which will randomise between preoperative SRS and postoperative FSRT.

Published
2022

3. Correction to: Stereotactic radiosurgery and radiotherapy for resected brain metastases: current pattern of care in the Radiosurgery and Stereotactic Radiotherapy Working Group of the German Association for Radiation Oncology (DEGRO)

Author

Rogers, S, Baumert, B, Blanck, O, Böhmer, D, Boström, J, Engenhart-Cabillic, R, Ermis, E, Exner, S, Guckenberger, M, Habermehl, D, Hemmatazad, H, Henke, G, Lohaus, F, Lux, S, Mai, S, Minasch, D, Rezazadeh, A, Steffal, C, Temming, S, Wittig, A, Zweifel, C, Riesterer, O, and Combs, S E

Subjects
Oncology, Radiology, Nuclear Medicine and imaging, 610 Medizin und Gesundheit
Published
2022
Full Text
View/download PDF

4. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)

Author

Balermpas, P., Rödel, F., Krause, M., Linge, A., Lohaus, F., Baumann, M., Tinhofer, I., Budach, V., Sak, A., Stuschke, M., Gkika, E., Grosu, A.-L., Abdollahi, A., Debus, J., Stangl, S., Ganswindt, U., Belka, C., Pigorsch, S., Multhoff, G., Combs, S. E., Welz, S., Zips, D., Lim, S. Y., Rödel, C., and Fokas, E.

Subjects
Male, HPV, Papillomavirus Infections, Programmed Cell Death 1 Receptor, Medizin, CD8, Chemoradiotherapy, Adjuvant, Middle Aged, Prognosis, PD-1/PD-L1, B7-H1 Antigen, SCCHN, chemoradiotherapy, Survival Rate, Head and Neck Neoplasms, Biomarkers, Tumor, Carcinoma, Squamous Cell, Humans, Female, Neoplasm Grading, prognostic, Papillomaviridae, Follow-Up Studies, Neoplasm Staging
Abstract

We examined the prognostic role of PD-1+ and CD8+ tumor infiltrating lymphocytes (TILs), and PD-L1+ cells in patients with squamous cell carcinoma of the head and neck (SCCHN) treated with surgery and postoperative chemoradiotherapy (CRT). FFPE samples from 161 patients were immunohistochemically stained for PD-1, CD8 and PD-L1. The immune marker expression was correlated with clinicopathologic characteristics, and overall survival (OS), local progression-free survival (LPFS) and distant metastases free-survival (DMFS), also in the context of HPV16 DNA/p16 status. The median follow-up was 48 months (range: 4-100). The 2-year-OS was 84.1% for the entire cohort. High PD-1 and PD-L1 expression were more common in patients with positive HPV16 DNA (p

Published
2017

5. Mutational patterns of HPV+ and HPV- squamous cell carcinomas of the head and neck (SCCHN) and their interference with outcome after adjuvant chemoradiation: A multicenter biomarker study of the German Cancer Consortium Radiation Oncology Group

Author

Tinhofer, I., Budach, V., Linge, A., Lohaus, F., Gkika, E., Stuschke, Martin, Balermpas, P., Rodel, C., Avlar, M., Grosu, A., Abdollahi, A., Debus, J., Belka, C., Pigorsch, S., Combs, S. E., Monnich, D., Zips, D., Weichert, W., Krause, M., Baumann, M., and DKTK-ROG

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Treatment outcome, Cell, Medizin, Cancer, medicine.disease, stomatognathic diseases, medicine.anatomical_structure, Internal medicine, Radiation oncology, medicine, Biomarker (medicine), Head and neck, business, Adjuvant
Abstract

6006 Background: The genetic landscape of SCCHN is currently being unravelled, but the role of distinct mutations for treatment outcome remains largely unknown. We compared mutational patterns of H...

Published
2015
Full Text
View/download PDF

7. Tumor Volume, HPV Status, and Cancer Stem Cell Marker Expression as prognostic Markers for the locoregional Tumor Control in Patients with locally advanced Head and Neck Squamous Cell Carcinoma after primary Chemoradiotherapy

Author

Linge, A., Schmidt, S., Krenn, C., Lohaus, F., Valentini, C., Neubeck, C., Appold, S., Gudziol, V., Nowak, A., Baretton, G. B., Frank Buchholz, Baumann, M., Krause, M., and Loeck, S.

Abstract

Fragestellung: Die prognostische Rolle des Tumorvolumens, des HPV-Status und der Expression des Krebsstammzellmarkers CD44 konnte kürzlich in einer Arbeit der Radioonkologie-Gruppe des Deutschen Konsortiums für Translationale Krebsforschung gezeigt werden. Ziel dieser Arbeit ist es, die prognostische Rolle dieser Marker in einer unabhängigen Kohorte zu validieren. Methodik: Diese Studie wurde an einer monozentrischen Kohorte von 78 Patienten mit lokal fortgeschrittenen Kopf-Hals-Plattenepithel- karzinomen der Mundhöhle, des Oropharynx und des Hypopharynx durchgeführt . Alle Patienten haben eine primäre Radiochemotherapie zwischen 1999 und 2011 mit einer medianen Gesamtdosis von 72 Gy erhalten. Der HPV-Surrogatmarker p16 und der Krebsstammzellmarker CD44 wurden immunhistochemisch untersucht . Die Genexpressionsanalyse von CD44 erfolgte mittels nanoString-Technologie. Das Tumorvolumen war von allen Patienten verfügbar und wurde durch einen Strahlentherapeuten erneut geprüft . Logistische und Cox-Regressionsmodelle wurden anhand der Fläche unter der Receiver-Operating-Characteristic-Kurve (AUC) sowie dem C-Index (ci) validiert. Der primäre Endpunkt dieser Studie ist die lokoregionale Tumorkontrolle. Ergebnis: Das Tumorvolumen war auch in dieser Studie signifikant mit dem Endpunkt der lokoregionalen Tumorkontrolle in der univariaten Analyse assoziiert (p = 0,009). Patienten mit CD44-negativen Tumoren entwickelten kein lokoregionales Rezidiv. In der multivariaten Cox-Regressionsanalyse bezüglich der Endpunkte der lokoregionalen Tumorkontrolle und des Gesamtüberlebens konnte die unabhängige Rolle des Tumorvolumens, des N-Status und des p16-Status bestätigt werden (lokoregionale Tumorkontrolle; ci: 0,64; Gesamtüberleben; ci: 0,68). Durch die zusätzliche Berücksichtigung der Genexpression von CD44 konnte das Modell leicht verbessert werden (lokoregionale Tumorkontrolle; ci: 0,65; Gesamtüberleben; ci: 0,72) . Das auf die Marker Tumorvolumen, p16-Status und CD44-Expression basierende logistische Regressionsmodell für die lokoregionale Kontrolle nach 2 Jahren konnte ebenfalls erfolgreich validiert werden (AUC: 0,70). Schlussfolgerung: Die prognostische Rolle des Tumorvolumens, des HPV-Status und des Krebsstammzellmarkers CD44 für Patienten mit lokal fortgeschrittenen Kopf-Hals-Plattenepithelkarzinomen, die eine primäre Radiochemotherapie erhalten haben, konnte in univariaten und in multivariaten Modellen bestätigt werden.

Catalog

Books, media, physical & digital resources
See catalog results